ATE373017T1 - Therapeutische verbindungen bestehend aus fc rezeptor bindenden wirkstoffen - Google Patents

Therapeutische verbindungen bestehend aus fc rezeptor bindenden wirkstoffen

Info

Publication number
ATE373017T1
ATE373017T1 AT00948934T AT00948934T ATE373017T1 AT E373017 T1 ATE373017 T1 AT E373017T1 AT 00948934 T AT00948934 T AT 00948934T AT 00948934 T AT00948934 T AT 00948934T AT E373017 T1 ATE373017 T1 AT E373017T1
Authority
AT
Austria
Prior art keywords
receptor
molecules
antigen
cell
multispecific
Prior art date
Application number
AT00948934T
Other languages
English (en)
Inventor
Yashwant Deo
Joel Goldstein
Robert Graziano
Tibor Keler
Original Assignee
Medarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/364,088 external-priority patent/US6365161B1/en
Application filed by Medarex Inc filed Critical Medarex Inc
Application granted granted Critical
Publication of ATE373017T1 publication Critical patent/ATE373017T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00948934T 1999-07-30 2000-07-25 Therapeutische verbindungen bestehend aus fc rezeptor bindenden wirkstoffen ATE373017T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/364,088 US6365161B1 (en) 1995-06-07 1999-07-30 Therapeutic compounds comprised of anti-FC receptor binding agents
US52327900A 2000-03-10 2000-03-10

Publications (1)

Publication Number Publication Date
ATE373017T1 true ATE373017T1 (de) 2007-09-15

Family

ID=27002335

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00948934T ATE373017T1 (de) 1999-07-30 2000-07-25 Therapeutische verbindungen bestehend aus fc rezeptor bindenden wirkstoffen

Country Status (12)

Country Link
EP (1) EP1212366B1 (de)
JP (2) JP4308470B2 (de)
KR (1) KR100816958B1 (de)
CN (1) CN1268645C (de)
AT (1) ATE373017T1 (de)
AU (1) AU779116B2 (de)
CA (1) CA2381565A1 (de)
DE (1) DE60036388D1 (de)
HK (1) HK1049170A1 (de)
IL (1) IL147766A0 (de)
MX (1) MXPA02000960A (de)
WO (1) WO2001009186A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
JP2005507635A (ja) 2001-02-12 2005-03-24 メダレックス， インク． Ｆｃα受容体（ＣＤ８９）に対するヒトモノクローナル抗体
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
HUP0600340A3 (en) * 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
US20040146948A1 (en) * 2002-10-18 2004-07-29 Centenary Institute Of Cancer Medicine And Cell Biology Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments
BG65715B1 (bg) * 2003-09-04 2009-08-31 Чавдар ВАСИЛЕВ Средство за селективно подтискане на патологични днк - специфични в клетки
UA97469C2 (uk) 2005-07-25 2012-02-27 Емерджент Продакт Дівелопмент Сіетл, Елелсі Гуманізована специфічна до cd37 зв'язувальна молекула імуноглобуліну
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
NZ603059A (en) 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
KR20140001257A (ko) 2008-05-13 2014-01-06 유니버시티 오브 캔사스 금속 추출 펩타이드(ｍａｐ) 태그 및 관련된 방법
ES2687974T3 (es) * 2012-03-14 2018-10-30 Regeneron Pharmaceuticals, Inc. Moléculas multiespecíficas de unión a antígeno y uso de las mismas
WO2013181461A2 (en) 2012-06-01 2013-12-05 University Of Kansas Metal abstraction peptide with superoxide dismutase activity
CN105407920B (zh) * 2013-05-03 2019-12-13 耶鲁大学 靶向癌症、尤其是前列腺癌的合成性抗体模拟化合物(SyAMs)
PL405768A1 (pl) * 2013-10-24 2015-04-27 Celther Polska Spółka Z Ograniczoną Odpowiedzialnością Zastosowanie agonistów EGFR i HGFR jako leków przeciwnowotworowych działających na komórki nowotworowe o określonym fenotypie
MY197218A (en) 2015-07-06 2023-06-02 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
EP3448891A1 (de) 2016-04-28 2019-03-06 Regeneron Pharmaceuticals, Inc. Verfahren zur herstellung multispezifischer antigenbindender moleküle
EP3241847A1 (de) * 2016-05-06 2017-11-08 MAB Discovery GmbH Her-2-bindende antikörper
WO2018140845A2 (en) * 2017-01-27 2018-08-02 Duke University Bi-specific antibodies to cd64 and a disease antigen
CA3118326A1 (en) * 2018-10-29 2020-05-07 Umc Utrecht Holding B.V. Iga mediated killing of aberrant cells by cd47- sirpalpha checkpoint inhibition of neutrophils
EP3947441A1 (de) 2019-03-27 2022-02-09 UMC Utrecht Holding B.V. Manipulierte iga-antikörper und verfahren zur verwendung
WO2022098084A1 (ko) * 2020-11-06 2022-05-12 고려대학교 산학협력단 Fc 알파 수용체 결합 항체

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6018031A (en) 1989-10-20 2000-01-25 Trustees Of Dartmouth College Binding agents specific for IgA receptor
ES2132072T3 (es) * 1989-10-20 1999-08-16 Dartmouth College Anticuerpo monoclonal especifico para receptor iga.
US5922845A (en) * 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies

Also Published As

Publication number Publication date
EP1212366B1 (de) 2007-09-12
CN1268645C (zh) 2006-08-09
CN1382157A (zh) 2002-11-27
WO2001009186A3 (en) 2001-05-31
CA2381565A1 (en) 2001-02-08
HK1049170A1 (zh) 2003-05-02
IL147766A0 (en) 2002-08-14
MXPA02000960A (es) 2002-07-02
AU6235800A (en) 2001-02-19
WO2001009186A2 (en) 2001-02-08
AU779116B2 (en) 2005-01-06
KR20020047103A (ko) 2002-06-21
JP4308470B2 (ja) 2009-08-05
JP2007119485A (ja) 2007-05-17
DE60036388D1 (de) 2007-10-25
JP2003522128A (ja) 2003-07-22
KR100816958B1 (ko) 2008-03-26
EP1212366A2 (de) 2002-06-12

Similar Documents

Publication Publication Date Title
ATE373017T1 (de) Therapeutische verbindungen bestehend aus fc rezeptor bindenden wirkstoffen
Ji et al. Enhanced natural killer cell immunotherapy by rationally assembling Fc fragments of antibodies onto tumor membranes
Ingram et al. Anti–CTLA-4 therapy requires an Fc domain for efficacy
Neri et al. Immunocytokines for cancer treatment: past, present and future
CN102083850B (zh) 选择性高亲和力多齿配体及其制备方法
CA2093022C (en) Targeted immunostimulation with bispecific reagents
Khera et al. Pharmacokinetic and immunological considerations for expanding the therapeutic window of next-generation antibody–drug conjugates
Binder et al. Saturation, competition, and specificity in interaction of heat shock proteins (hsp) gp96, hsp90, and hsp70 with CD11b+ cells
Attarwala Role of antibodies in cancer targeting
Glaffig et al. A synthetic MUC1 anticancer vaccine containing mannose ligands for targeting macrophages and dendritic cells
Oude Munnink et al. Lapatinib and 17AAG reduce 89Zr-trastuzumab-F (ab′) 2 uptake in SKBR3 tumor xenografts
JP2016509582A5 (de)
BR0207283A (pt) Anticorpos anti-egfr modificados com imunogenicidade reduzida
Cho et al. Single-chain Fv/folate conjugates mediate efficient lysis of folate-receptor-positive tumor cells
KR20200085942A (ko) 페르투주맙 변이체 및 그의 평가
Simpson et al. Monoclonal antibodies for the therapy of cancer
US20180271997A1 (en) Methods and Reagents to Treat Tumor and Cancer
Fletcher et al. Formation of immune complexes with a tetanus-derived B cell epitope boosts human T cell responses to covalently linked peptides in an ex vivo blood loop system
WO2018231661A1 (en) Methods and reagents to treat tumor and cancer
Hong et al. Chemoenzymatic Synthesis of a Rhamnose‐Functionalized Bispecific Nanobody as a Bispecific Antibody Mimic for Cancer Immunotherapy
Fujimura et al. Conjugation ratio, light dose, and pH affect the stability of panitumumab–IR700 for near-infrared photoimmunotherapy
CZ43798A3 (cs) Fúzní proteiny, způsob jejich přípravy a farmaceutický přípravek, který je obsahuje
EP2155250B1 (de) Kohlenhydrathaltiger pan-tumormarker
De Silva et al. The entirely carbohydrate immunogen Tn-PS A1 induces a cancer cell selective immune response and cytokine IL-17
Li et al. Chemical remodeling cell surface glycans for immunotargeting of tumor cells

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties